![]() |
left to right, Dr Asmerom Sengal, Professor Pamela Pollock. Photo Credit: Courtesy of Queensland University of Technology |
QUT scientists have discovered a promising new therapy for a deadly type of endometrial cancer that has a poor prognosis if the cancer spreads or returns after initial treatment, a plight that affects 15-20 per cent of endometrial cancer patients.
- Testing of new drug inhibited uterine tumor cell growth in lab and mice models
- The drug blocks the receptor of the growth factor in tumors that is associated with a low survival rate
- The inhibitor also reduced the tumors blood vessel formation
Dr Asmerom Sengal and Associate Professor Pamela Pollock from QUT’s School of Biomedical Sciences, published their research in Nature Precision Oncology with a recommendation that the strength of their findings indicated they should proceed to patient trials.
Dr Asmerom said endometrial cancer confined within the uterus could be cured with surgery however, if it had spread to the abdomen and other organs patients had limited treatment options.
“Previously, we found women with endometrial cancer who have an incorrect growth factor receptor called fibroblast growth factor receptor 2c (FGFR2c) on the tumor cell surface have a poor survival rate,” Dr Asmerom said.